Related Experiment Video
Updated: Jun 26, 2025

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
Published on: April 10, 2019
Detailed role of mesenchymal stem cell (MSC)-derived exosome therapy in cardiac diseases
Ali Hassanzadeh1, Navid Shomali2,3, Amin Kamrani2,3
1Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Insights
Mesenchymal stem cell (MSC) exosomes show therapeutic potential for cardiac diseases by delivering beneficial molecules. These extracellular vesicles, not the cells themselves, aid in healing injured cardiac tissue and offer a promising new treatment avenue.
Area of Science:
- Cardiovascular Research
- Regenerative Medicine
- Cell Biology
Background:
- Coronary heart disease (CHD) remains a primary cause of death, with current treatments unable to prevent cardiomyocyte death from ischemia/reperfusion (I/R) injury.
- Mesenchymal stem cells (MSCs) are explored for cardiac tissue regeneration, but their therapeutic effects stem from secreted factors, not differentiation.
- Exosomes, extracellular vesicles released by MSCs, carry therapeutic cargo like proteins and miRNAs, mediating intercellular communication and tissue repair.
Purpose of the Study:
- To review the therapeutic potential of exosomes derived from mesenchymal stem cells (MSCs) for treating cardiac diseases.
- To highlight the role of exosome-mediated paracrine signaling in cardiac tissue repair following injury.
- To summarize recent advancements in the application of exosomal MSCs in cardiovascular medicine.
Main Methods:
- Review of existing scientific literature on mesenchymal stem cell (MSC) therapy and exosome biology in cardiac contexts.
- Analysis of studies investigating the mechanisms of exosome-mediated intercellular communication in myocardial I/R injury.
- Synthesis of data from animal models demonstrating the therapeutic efficacy of MSC-derived exosomes.
Main Results:
- Mesenchymal stem cell (MSC)-derived exosomes mediate therapeutic effects in various cardiac disease models.
- Exosomes deliver functional molecules (miRNAs, proteins) that promote cardiac tissue healing and reduce cardiomyocyte death.
- The therapeutic benefits of MSCs in cardiac conditions are largely attributable to their secreted exosomes.
Conclusions:
- Mesenchymal stem cell (MSC)-derived exosomes represent a cell-free therapeutic strategy for cardiac diseases.
- Exosomes offer a promising alternative to cell-based therapies, with potential for enhanced safety and efficacy in treating myocardial I/R injury.
- Further research into exosomal MSCs is warranted to advance their clinical application in cardiovascular medicine.
Abstract:
Coronary heart disease (CHD) continues to be the leading cause of morbidity and mortality. There are numerous therapeutic reperfusion methods, including thrombolytic therapy, primary percutaneous coronary intervention, and anti-remodeling drugs like angiotensin-converting enzyme inhibitors and beta-blockers. Despite this, there is no pharmacological treatment that can effectively stop cardiomyocyte death brought on by myocardial ischemia/reperfusion (I/R) injury. For the purpose of regenerating cardiac tissue, mesenchymal stem cell (MSC) therapy has recently gained more attention. The pleiotropic effects of MSCs are instead arbitrated by the secretion of soluble paracrine factors and are unrelated to their capacity for differentiation. One of these paracrine mediators is the extracellular vesicle known as an exosome. Exosomes deliver useful cargo to recipient cells from MSCs, including peptides, proteins, cytokines, lipids, miRNA, and mRNA molecules. Exosomes take part in intercellular communication processes and help tissues and organs that have been injured or are ill heal. Exosomes alone were found to be the cause of MSCs' therapeutic effects in a variety of animal models, according to studies. Here, we have focused on the recent development in the therapeutic capabilities of exosomal MSCs in cardiac diseases.
Related Concept Videos
Mesenchymal Stem Cells
Overview of Exosomes
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

